*Terms & Conditions apply.
Study Information
Simbec-Orion Clinical Pharmacology will soon be running a first-in-human study to investigate a new potential medicine. The primary objectives of this study are to determine the safety and tolerability of the drug when administered as a single dose at various strengths during one session to participants who are overweight or living with obesity.
This study will be split into two aspects; Dosing Group One and Dosing Group Two and you will only participate in one cohort in one of the dosing groups.
Dosing Group One
A minimum of 2 screening visits must be completed within 35 days of dosing. If you participate in a cohort in dosing group one, you will be required to stay at the Simbec-Orion clinical unit for 4 days (3 overnight stays) for the in-house stay.
Following the overnight stays listed above, there will be a telephone call and 15 return visits for 10 months following dosing. In addition to these visits, you will also have the option to complete one additional return visit,12 months following dosing.
If you participate in this study, you will receive an inconvenience payment for the inconvenience of participating in and satisfactorily completing the study including all procedures and the post-trial follow up visit, along with the highest level of compliance.
The payment will be also split across the study, and you will receive set payments following completion of certain visits throughout the study. The maximum reimbursement and inconvenience fee for participating in this group/cohort is £9,830.
Dosing Group Two
A minimum of 2 screening visits must be completed within 35 days of dosing. If you participate in a cohort in dosing group two, you will be required to stay at the Simbec-Orion clinical unit for 2 days (1 overnight stay) for the in-house stay.
Following the overnight stay listed above, there will be a telephone call and 17 return visits for 10 months following dosing. In addition to these visits, you will also have the option to complete one additional return visit,12 months following dosing.
If you participate in this study, you will receive an inconvenience payment for the inconvenience of participating in and satisfactorily completing the study including all procedures and the post-trial follow up visit, along with the highest level of compliance.
The payment will be also split across the study, and you will receive set payments following completion of certain visits throughout the study. The maximum reimbursement and inconvenience fee for participating in this group/cohort is £9,778.
